Experimental Hematology & Oncology

Experimental Hematology & Oncology is a peer-reviewed open-access online journal published by BioMed Central (BMC, part of Springer Nature) that was founded in 2012 and encompasses all aspects of hematology and oncology, with a 2025 Journal Impact Factor of 17.5《实验血液学与肿瘤学》是由施普林格·自然（Springer Nature）旗下的（BioMed Central）出版的同行评审开放获取在线期刊，2012 年创办，涵盖血液学与肿瘤学的所有方面，2025 年影响因子为 17.5。

Scope

• It encompasses all aspects of hematology and oncology, with an emphasis on preclinical, basic, patient-oriented and translational research该刊涵盖血液学与肿瘤学的所有方面，着重于临床前、基础、面向患者与转化研究。
• It acts as an international platform for sharing laboratory findings in these closely related fields该刊是分享这些紧密相关领域实验室发现的国际平台。
• It makes a deliberate effort to publish clinical trials with negative results and basic science studies with provocative findings该刊刻意致力于发表结果为阴性的临床试验与结论具争议性的基础研究。
• It publishes original work, hypotheses, commentaries and timely reviews该刊刊载原创研究、假设、评论与及时的综述。
• It aims to be a hub for disseminating new knowledge and discussing controversial topics for basic scientists and clinicians该刊旨在成为传播新知识、供基础科学家与临床医师讨论争议性议题的枢纽。
• As an open access journal it publishes articles as soon as they are ready and makes them freely accessible without subscription or registration barriers作为开放获取期刊，文章一经就绪即行发表，无需订阅或注册即可自由获取。
• Article types include research, review, correspondence, case report, editorial and commentary文章类型包括研究、综述、通讯、病例报告、社论与评论。

History

• The journal was founded in 2012, with its first volume published that year and the founding editorial released online on 26 March 2012该刊于 2012 年创办，同年出版第 1 卷，创刊社论于 2012 年 3 月 26 日在线发表。^[1]
• It is the companion journal of Journal of Hematology & Oncology该刊是《血液学与肿瘤学杂志》的姊妹刊。
• It is published by BioMed Central, part of Springer Nature, and appears online only without a print edition该刊由施普林格·自然（Springer Nature）旗下的（BioMed Central）出版，仅在线发行，无印刷版。
• It has been fully open access since launch, with authors retaining copyright and granting third parties rights under the BMC license agreement该刊自创刊起即为完全开放获取，作者保留版权，并依据（BMC）许可协议授予第三方使用权。
• Its Journal Impact Factor rose from 5.133 in 2021 and 8.593 in 2022 to 13.5 in 2024 and 17.5 in 2025其影响因子由 2021 年的 5.133、2022 年的 8.593 升至 2024 年的 13.5 与 2025 年的 17.5。
• In the 2025 Journal Citation Reports it ranks Q1 in both hematology and oncology在 2025 年期刊引证报告中，该刊在血液学与肿瘤学两个类别均位列 Q1。
• It is indexed in PubMed, PubMed Central, Scopus, Embase and the Science Citation Index Expanded该刊被（PubMed）、（PubMed Central）、（Scopus）、（Embase）与（Science Citation Index Expanded）收录。

Editors

• Its Editors-in-Chief are Delong Liu of New York Medical College, USA and Kongming Wu of Tongji Medical College of Huazhong University of Science and Technology, China现任主编为刘德龙（Delong Liu），来自（New York Medical College），以及吴孔明（Kongming Wu），来自（Tongji Medical College of Huazhong University of Science and Technology）。
• The Founding Editor is Zihai Li of The Ohio State University, USA创刊编辑为 Zihai Li，来自（The Ohio State University）。
• It is supported by an expert international editorial board该刊由国际专家编委会支持。
• It operates a single-blind peer-review system, in which reviewers know author names but the reports sent to authors are anonymous该刊采用单盲同行评审制度，评审人知晓作者身份，而送交作者的评审报告匿名。
• Each manuscript is generally reviewed by two or more experts每篇稿件通常由两名或以上专家评审。
• The Editors reach a decision based on these reports and may consult members of the Editorial Board编辑依据这些报告作出决定，必要时会咨询编委会成员。